Citigroup started coverage on shares of Bausch Health Companies (NYSE:BHC) in a research note released on Friday morning, The Fly reports. The firm issued a buy rating and a $30.00 target price on the
Bausch Health Companies (NYSE:BHC) initiated with Buy rating and $30 (84% upside) price target at Citigroup. Shares up 1% premarket.Radius Health (NASDAQ:RDUS) initiated with Hold rating and $20 (16
Largest borrow rate increases among liquid names SKT I GSX BHC WLL RSX FSLY BB IQ
In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC), with a price target of $28.00. The
In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research
Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.
Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Bank of New York Mellon Corp lowered its holdings in shares of Bausch Health Companies Inc (NYSE:BHC) by 2.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Ex
Optimism that the worst might be over with the COVID-19 outbreak fueled investors' enthusiasm for these healthcare stocks.
Following up on its initial announcements in January and February, Incyte (NASDAQ:INCY) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2, evaluating a topica
Exact Sciences (NASDAQ:EXAS) initiated with an Outperform rating and a $70 (25% upside) price target at Evercore ISI.Health Catalyst (NASDAQ:HCAT) initiated with a Buy rating and a $40 (47% upside) pr
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bausch Health Companies (BHC) today and set a price target of $50.00. The company's
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bausch Health Companies (BHC – Research Report) today and set
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE